
Cat. #162375
Anti-PAX9 monoclonal antibody [PAX9 7C2]
Cat. #: 162375
Sub-type: Primary antibody
Target: Human/murine PAX9
Class: Monoclonal
Application: WB
Reactivity: Human, mouse
Host: Rat
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: Helmholtz Munich Core Facility Monoclonal Antibodies
Primary Citation: Gerber et al. 2002. J. Pathol. 197: 293-297. PMID: 12115874
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-PAX9 monoclonal antibody [PAX9 7C2]
- Alternate name: Anti human/murine PAX9 monoclonal antibody (clone PAX9 7C2)
- Cancer type: Lung cancer, Head and neck cancer
- Research fields: Cell biology;Cell signaling and signal transduction;Developmental biology
- Clone: PAX9 7C2
- Tool type ecom: Antibody
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Reactivity: Human, mouse
- Host: Rat
- Disease: Cancer
- Application: WB
- Isotype: IgG1, k
Target Details
- Target: Human/murine PAX9
- Target alternate names: Paired Box Protein Pax-9, STHAG3
- Target background: PAX9 has prognostic significance in esophageal squamous cell carcinoma (ESCC) and predicts radiation sensitivity. Progressive loss of PAX9 expression correlates with increasing malignancy of dysplastic and cancerous epithelium of the human oesophagus. PAX9 expression has been shown to mediate oncogene-induced cell survival in oral squamous cell carcinoma (Lee et al., 2008). On the other hand progressive loss of PAX9 expression correlates with increasing malignancy in esophageal cancers (Gerber et al., 2002)
Applications
- Application: WB
References
- Gerber et al. 2002. J. Pathol. 197: 293-297. PMID: 12115874
- Jonker et al. 2004. Mech. Dev. 121: 1313-1322. PMID: 15454262

![Anti-CAR Whitlow Linker [1C3C3]](https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-300x322.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-280x300.jpg 280w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-954x1024.jpg 954w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-768x824.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 1193w)
